公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
2021 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU ; Yu M.-L. | Hepatology International | 4 | 5 | |
2021 | Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan | Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators | Journal of Gastroenterology and Hepatology (Australia) | 2 | 3 | |
2010 | Moscatilin repressed lipopolysaccharide-induced hif-1α accumulation and NF-κB activation in murine raw264.7 cells | Liu Y.-N.; Pan S.-L.; Peng C.-Y.; Huang D.-Y.; JIH-HWA GUH ; Chen C.-C.; Shen C.-C.; Teng C.-M. | Shock | 28 | 26 | |
2021 | Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan | Huang C.-F.; Kuo H.-T.; Chang T.-S.; Lo C.-C.; Hung C.-H.; Huang C.-W.; Chong L.-W.; Cheng P.-N.; Yeh M.-L.; Peng C.-Y.; Cheng C.-Y.; Huang J.-F.; Bair M.-J.; Lin C.-L.; Yang C.-C.; Wang S.-J.; Hsieh T.-Y.; Lee T.-H.; Lee P.-L.; Wu W.-C.; Lin C.-L.; Su W.-W.; Yang S.-S.; Wang C.-C.; Hu J.-T.; Mo L.-R.; Chen C.-T.; Huang Y.-H.; Chang C.-C.; Huang C.-S.; Chen G.-Y.; Kao C.-N.; Tai C.-M.; CHUN-JEN LIU ; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; JIA-HORNG KAO ; Lin H.-C.; Chuang W.-L.; Chen C.-Y.; Tseng K.-C.; Yu M.-L. | Scientific Reports | 9 | 5 | |
2018 | A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment | Liu Y.-T.; TAI-CHUNG TSENG ; Soong R.-S.; Peng C.-Y.; Cheng Y.-H.; Huang S.-F.; Chuang T.-H.; JIA-HORNG KAO ; Huang L.-R. | Journal for ImmunoTherapy of Cancer | 32 | 29 | |
2021 | One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment | TAI-CHUNG TSENG ; Choi J.; Nguyen M.H.; Peng C.-Y.; Siakavellas S.; Papatheodoridis G.; Wang C.-C.; Lim Y.-S.; Lai H.-C.; Trinh H.N.; Wong C.; Wong C.; Zhang J.; Li J.; JIA-HORNG KAO | Hepatology International | 5 | 7 | |
2020 | An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients with Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions | Huang C.-F.; Hung C.-H.; Cheng P.-N.; Bair M.-J.; Huang Y.-H.; JIA-HORNG KAO ; SHIH-JER HSU ; Lee P.-L.; Chen J.-J.; Chien R.-N.; Peng C.-Y.; Lin C.-Y.; Hsieh T.-Y.; Cheng C.-H.; Dai C.-Y.; Huang J.-F.; Chuang W.-L.; Yu M.-L. | Journal of Infectious Diseases | 15 | 11 | |
2017 | Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients | Phillips S.; Mistry S.; Riva A.; Cooksley H.; Hadzhiolova-Lebeau T.; Plavova S.; Katzarov K.; Simonova M.; Zeuzem S.; Woffendin C.; PEI-JER CHEN ; Peng C.-Y.; Chang T.-T.; Lueth S.; Knegt R.D.; Choi M.-S.; Wedemeyer H.; Dao M.; Kim C.-W.; Chu H.-C.; Wind-Rotolo M.; Williams R.; Cooney E.; Chokshi S. | Frontiers in Immunology | 51 | 42 | |
2019 | Peginterferon alfa-2a (40 kD) stopping rules in chronic hepatitis B: A systematic review and meta-analysis of individual participant data | Pavlovic V.; Yang L.; Chan H.L.-Y.; Hou J.; Janssen H.L.; JIA-HORNG KAO ; Lampertico P.; Peng C.-Y.; Piratvisuth T.; Thompson A.J.; Wedemeyer H.; Wei L.; Wat C. | Antiviral Therapy | 10 | 7 | |
2016 | Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: A randomized phase 2b study (LIRA-B) | Chan H.L.Y.; Ahn S.H.; Chang T.-T.; Peng C.-Y.; Wong D.; Coffin C.S.; Lim S.G.; PEI-JER CHEN ; Janssen H.L.A.; Marcellin P.; Serfaty L.; Zeuzem S.; Cohen D.; Critelli L.; Xu D.; Wind-Rotolo M.; Cooney E.; LIRA-B Study Team | Journal of Hepatology | 84 | 69 | |
2016 | A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection | JIA-HORNG KAO ; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. | Liver International | 25 | 25 | |
2018 | Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B | Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO ; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F. | Journal of the Formosan Medical Association | 20 | 17 | |
2005 | A potential role of YC-I on the inhibition of cytokine release in peripheral blood mononuclear leukocytes and endotoxemic mouse models | Pan S.-L.; JIH-HWA GUH ; Peng C.-Y.; Chang Y.-L.; Cheng F.-C.; Chang J.-H.; Kuo S.-C.; Lee F.-Y.; Teng C.-H. | Thrombosis and Haemostasis | 32 | 31 | |
2022 | Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine | Park J.; Le A.K.; TAI-CHUNG TSENG ; Yeh M.-L.; Jun D.W.; Trinh H.; Wong G.L.H.; Chen C.-H.; Peng C.-Y.; Kim S.E.; Oh H.; Kwak M.-S.; Cheung K.S.; Toyoda H.; Hsu Y.-C.; Jeong J.Y.; Yoon E.L.; Ungtrakul T.; Zhang J.; Xie Q.; Ahn S.B.; Enomoto M.; Shim J.-J.; Cunningham C.; Jeong S.W.; Cho Y.K.; Ogawa E.; Huang R.; Lee D.-H.; Takahashi H.; Tsai P.-C.; Huang C.-F.; Dai C.-Y.; Tseng C.-H.; Yasuda S.; Kozuka R.; Li J.; Wong C.; Wong C.C.; Zhao C.; Hoang J.; Eguchi Y.; Wu C.; Tanaka Y.; Gane E.; Tanwandee T.; Cheung R.; Yuen M.-F.; Lee H.-S.; Yu M.-L.; JIA-HORNG KAO ; Yang H.-I.; Nguyen M.H. | Clinical Gastroenterology and Hepatology | 3 | 4 | |
2013 | Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients | Yuan Q.; Song L.-W.; CHUN-JEN LIU ; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; JIA-HORNG KAO ; DING-SHINN CHEN ; PEI-JER CHEN ; Xia N.-S. | Gut | 67 | 63 | |
2015 | Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients | Yang C.-C.; Tsai W.-L.; Su W.-W.; Huang C.-F.; Cheng P.-N.; Lo C.-C.; Tseng K.-C.; Mo L.-R.; Wang C.-H.; SHIH-JER HSU ; Lai H.-C.; Su C.-W.; CHUN-JEN LIU ; Peng C.-Y.; Yu M.-L. | PLoS ONE | 8 | 5 | |
2012 | Rather than interleukin-27, interleukin-6 expresses positive correlation with liver severity in naïve hepatitis B infection patients | Kao J.-T.; Lai H.-C.; Tsai S.-M.; Lin P.-C.; Chuang P.-H.; Yu C.-J.; Cheng K.-S.; Su W.-P.; PING-NING HSU ; Peng C.-Y.; Wu Y.-Y. | Liver International | 47 | 40 | |